Lv11
28 积分 2022-03-24 加入
High time for risk-adapted treatment in mantle cell lymphoma
7小时前
待确认
Rituximab maintenance following frontline bendamustine-rituximab in mantle cell lymphoma: a systematic review and meta-analysis
7小时前
已完结
Rocbrutinib: First Approval
9小时前
已完结
Exploration of efficacy and safety of combined therapy of basiliximab with ruxolitinib for grade 3–4 steroid-refractory acute graft-versus-host disease: a registered clinical trial (NCT05021276)
5个月前
已完结
Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure
5个月前
已完结
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
5个月前
已完结
Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia
5个月前
已完结
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
5个月前
已完结
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma
6个月前
已完结
Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia
6个月前
已完结
皖公网安备34019202002308
